Molecular basis of human immunodeficiency virus drug resistance: an update
- PMID: 19616029
- DOI: 10.1016/j.antiviral.2009.07.006
Molecular basis of human immunodeficiency virus drug resistance: an update
Abstract
Antiretroviral therapy has led to a significant decrease in human immunodeficiency virus (HIV)-related mortality. Approved antiretroviral drugs target different steps of the viral life cycle including viral entry (coreceptor antagonists and fusion inhibitors), reverse transcription (nucleoside and non-nucleoside inhibitors of the viral reverse transcriptase), integration (integrase inhibitors) and viral maturation (protease inhibitors). Despite the success of combination therapies, the emergence of drug resistance is still a major factor contributing to therapy failure. Viral resistance is caused by mutations in the HIV genome coding for structural changes in the target proteins that can affect the binding or activity of the antiretroviral drugs. This review provides an overview of the molecular mechanisms involved in the acquisition of resistance to currently used and promising investigational drugs, emphasizing the structural role of drug resistance mutations. The optimization of current antiretroviral drug regimens and the development of new drugs are still challenging issues in HIV chemotherapy. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.Antiviral Res. 2013 Apr;98(1):93-120. doi: 10.1016/j.antiviral.2013.01.007. Epub 2013 Feb 8. Antiviral Res. 2013. PMID: 23403210 Review.
-
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).Antiviral Res. 2010 Jan;85(1):75-90. doi: 10.1016/j.antiviral.2009.09.008. Epub 2009 Sep 23. Antiviral Res. 2010. PMID: 19781578 Review.
-
Clinical management of HIV-1 resistance.Antiviral Res. 2010 Jan;85(1):245-65. doi: 10.1016/j.antiviral.2009.09.015. Epub 2009 Oct 4. Antiviral Res. 2010. PMID: 19808056 Review.
-
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.Antiviral Res. 2010 Jan;85(1):59-74. doi: 10.1016/j.antiviral.2009.10.003. Epub 2009 Oct 22. Antiviral Res. 2010. PMID: 19853627 Review.
Cited by
-
Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Antimicrob Agents Chemother. 2013 Jul;57(7):3100-9. doi: 10.1128/AAC.00348-13. Epub 2013 Apr 22. Antimicrob Agents Chemother. 2013. PMID: 23612196 Free PMC article.
-
Evolutionary biochemistry: revealing the historical and physical causes of protein properties.Nat Rev Genet. 2013 Aug;14(8):559-71. doi: 10.1038/nrg3540. Nat Rev Genet. 2013. PMID: 23864121 Free PMC article. Review.
-
The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Viruses. 2010 Jan 28;2(2):372-394. doi: 10.3390/v2020372. Viruses. 2010. PMID: 20523911 Free PMC article.
-
Prediction and molecular field view of drug resistance in HIV-1 protease mutants.Sci Rep. 2022 Feb 21;12(1):2913. doi: 10.1038/s41598-022-07012-x. Sci Rep. 2022. PMID: 35190671 Free PMC article.
-
Intergenerational phenotypic mixing in viral evolution.Evolution. 2013 Jun;67(6):1815-22. doi: 10.1111/evo.12048. Epub 2013 Feb 4. Evolution. 2013. PMID: 23730772 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
